HomeCompareBBIXF vs MAIN

BBIXF vs MAIN: Dividend Comparison 2026

BBIXF yields 1666.67% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBIXF wins by $1839785618.31M in total portfolio value
10 years
BBIXF
BBIXF
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full BBIXF calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — BBIXF vs MAIN

📍 BBIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBIXFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBIXF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBIXF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBIXF
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, BBIXF beats the other by $1,398,727,281,850,960.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBIXF + MAIN for your $10,000?

BBIXF: 50%MAIN: 50%
100% MAIN50/50100% BBIXF
Portfolio after 10yr
$919892857.10M
Annual income
$822,780,794,238,676.00/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

BBIXF
No analyst data
Altman Z
-19.8
Piotroski
2/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBIXF buys
0
MAIN buys
0
No recent congressional trades found for BBIXF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBIXFMAIN
Forward yield1666.67%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$1839785666.26M$47.95M
Annual income after 10y$1,645,561,548,268,653.00$40,208,699.11
Total dividends collected$1825787439.21M$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: BBIXF vs MAIN ($10,000, DRIP)

YearBBIXF PortfolioBBIXF Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$177,367$166,666.67$12,464$1,223.78+$164.9KBBIXF
2$2,952,503$2,762,720.66$16,353$2,343.58+$2.94MBBIXF
3$46,139,686$42,980,507.73$23,105$4,724.42+$46.12MBBIXF
4$677,098,258$627,728,794.51$36,226$10,256.23+$677.06MBBIXF
5$9,333,745,461$8,609,250,324.41$65,426$24,707.64+$9333.68MBBIXF
6$120,900,966,251$110,913,858,608.07$142,101$68,562.02+$120900.82MBBIXF
7$1,472,054,345,780$1,342,690,311,890.92$388,521$228,799.95+$1472053.96MBBIXF
8$16,853,789,214,559$15,278,691,064,574.45$1,397,868$961,169.80+$16853787.82MBBIXF
9$181,517,867,281,133$163,484,312,821,554.84$6,884,663$5,313,459.69+$181517860.40MBBIXF
10$1,839,785,666,259,465$1,645,561,548,268,653.00$47,947,060$40,208,699.11+$1839785618.31MBBIXF

BBIXF vs MAIN: Complete Analysis 2026

BBIXFStock

Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone trauma and arthritis. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.

Full BBIXF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this BBIXF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBIXF vs SCHDBBIXF vs JEPIBBIXF vs OBBIXF vs KOBBIXF vs ARCCBBIXF vs HTGCBBIXF vs GBDCBBIXF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.